Mayara Rodrigues Brandao de Paiva

Dr. Mayara Rodrigues Brandao de Paiva

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020 in Journal of Biomaterials Applications
Verified
Journal Article
Closed access
PDF file
MPMayara Rodrigues Brandao de Paiva
Mayara Rodrigues Brandao de Paiva
GAGracielle Ferreira Andrade
Gracielle Ferreira Andrade
LDLays Fernanda Nunes Dourado
Lays Fernanda Nunes Dourado
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
SFSilvia Ligório Fialho
Silvia Ligório Fialho
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior
Tacrolimus (TAC), a potent immunosuppressive macrolide, has been investigated for ocular diseases due to promising results in the treatment of anterior and posterior segments eye diseases. Mesoporous and functionalized silica nanoparticles show potential as TAC delivery platforms owing to their interesting characteristic as large surface area, uniform pore size distribution, high pore volume, and excellent biocompatibility. The purpose of this study was to incorporate TAC in functionalized silica nanoparticles with 3-aminopropyltriethoxysilane (MSNAPTES) and investigate the safety and biocompatibility of the systems. The MSNAPTES and MSNAPTES TAC nanoparticles were characterized. The in vitro cytotoxicity of MSNAPTES and MSNAPTES load with TAC (MSNAPTES-TAC) in retinal pigment epithelial cells (ARPE-19) was determined, chorioallantoic membrane (CAM) assay model was used to investigate the in vivo biocompatibility, and safety of intravitreal injection was evaluated using clinical examination (assessment of intraocular pressure and indirect fundus ophthalmoscopy), electroretinographic (ERG) and histologic studies in rats’ eyes. The elemental analysis (CHN), thermogravimetric (TGA), photon correlation spectroscopy and Fourier transform infrared (FTIR) analysis confirmed the presence of functionalized agent and TAC in the MSNAPTES nanoparticles. TAC loading was estimated at 7% for the MSNAPTES TAC nanoparticles. MSNAPTES and MSNAPTES TAC did not present in vitro cytotoxicity. The drug delivery systems showed good biocompatibility on CAM. No retinal abnormalities, vitreous hemorrhage, neovascularization, retinal detachment, and optic nerve atrophy were observed during the in vivo study. Follow-up ERGs showed no changes in the function of the retina cells after 15 days of intravitreal injection, and histopathologic observations support these findings. In conclusion, MSNAPTES TAC was successfully synthesized, and physicochemical analyses confirmed the presence of TAC in the nanoparticles. In vitro and in vivo studies indicated that MSNAPTES TAC was safe to intravitreal administration. Taking into account the enormous potential of MSNAPTES to carry TAC, this platform could be a promising strategy for TAC ocular drug delivery in the treatment of eye diseases.

6 January 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MPMayara Rodrigues Brandao de Paiva
Mayara Rodrigues Brandao de Paiva
DVDaniel Vítor Vasconcelos-Santos
Daniel Vítor Vasconcelos-Santos
LVLorena Carla Vieira
Lorena Carla Vieira
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior

10 September 2025 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Open access
DSDominique Mesquita e Silva
Dominique Mesquita e Silva
LLLaís de Souza Lacerda
Laís de Souza Lacerda
AAAndrea de Souza Andrioli
Andrea de Souza Andrioli
WBWilson Rodrigues Braz
Wilson Rodrigues Braz
LCLara Melo Campos
Lara Melo Campos
GTGuilherme Diniz Tavares
Guilherme Diniz Tavares
This review highlights the integration of drug repurposing and nanotechnology‐driven delivery strategies as innovative approaches to enhance the antifungal activity of statins against mucosal candidiasis, providing a framework for future translational research and clinical application. The rising prevalence of antifungal resistance and virulence factors of Candida albicans underscore the limitations of current therapies. Statins, commonly used as lipid‐lowering agents, have emerged as attractive repurposed drug candidates due to their ability to interfere with fungal ergosterol biosynthesis and Ras‐mediated signaling pathways. However, repurposed statins face major translational barriers, including poor water solubility, limited mucosal bioavailability, and dose‐dependent systemic toxicity. Nanotechnology‐driven delivery platforms offer versatile solutions to these challenges, enabling site‐directed delivery, improved stability, enhanced permeability, and controlled release. Lipid and polymeric nanocarriers, particularly chitosan‐based nanoparticles, enable controlled release and prolonged mucosal retention, making them suitable for localized antifungal therapy. This review explores the integration of statin repurposing with advanced drug delivery strategies as a novel therapeutic paradigm for mucosal candidiasis. Updated evidence demonstrating the antifungal potential of nano‐formulated statins is summarized, in conjunction with a general overview of design aspects relevant to optimizing delivery systems. Although still in early stages of investigation, this synergistic approach holds promise for overcoming resistance mechanisms and reducing the recurrence rates associated with existing antifungals. Ultimately, leveraging drug repurposing alongside nanotechnology may accelerate the translation of statin‐based antifungal therapies into clinical practice, providing an innovative and cost‐effective avenue to broaden the therapeutic arsenal against mucosal Candida infections.

1 November 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Cibele Rodrigues ToledoCibele Rodrigues Toledo
Cibele Rodrigues Toledo
MPMayara Rodrigues Brandao de Paiva
Mayara Rodrigues Brandao de Paiva
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
VPVinicius Viana Pereira
Vinicius Viana Pereira
SCSarah Pereira de Freitas Cenachi
Sarah Pereira de Freitas Cenachi
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior
Lupeol is a pentacyclic triterpene with known anti-inflammatory effects. However, its role in the treatment of noninfectious uveitis has not been explored. This work investigated anti-inflammatory activity of lupeol in ocular tissues with in vitro and in vivo models. First, we evaluated the effect of lupeol (100 µM) on inflammatory response induced by lipopolysaccharide (LPS) in retinal pigment epithelium cells (ARPE-19) by measuring levels of released interleukins (IL-6 and IL-8). Then, we investigated the anti-inflammatory action of intravitreal lupeol in a rodent model of panuveitis induced by Mycobacterium bovis Calmette-Guérin Bacillus (BCG). Rats were submitted to electroretinography and clinical analyses on days 3, 7, and 15 after uveitis induction. In addition, histopathological analysis, and indirect quantification of myeloperoxidase (MPO) and N-acetylglucosaminidase (NAG) in the posterior segment were performed. Treatment with lupeol (100 µM) significantly decreased IL-6 and IL-8 levels in comparison to untreated LPS-activated ARPE-19 cells. This reduction was similar to that detected in ARPE-19 cells treated with dexamethasone. The results of the in vivo assay demonstrated that intravitreal lupeol is able to modulate inflammation in the anterior and posterior segment of the rat eyes, indicating that it should be further investigated as a novel potential candidate for management of uveitis.

1 January 2023 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
LMLutiana Amaral de Melo
Lutiana Amaral de Melo
MPMayara Rodrigues Brandao de Paiva
Mayara Rodrigues Brandao de Paiva
GFGabriella Maria Fernandes-Cunha
Gabriella Maria Fernandes-Cunha
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior
MMMarcos Mol
Marcos Mol
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
Ocular toxoplasmosis is the leading cause of infectious posterior uveitis worldwide, accounting for 30-50% of all cases in immunocompetent patients. Conventional treatment is associated with adverse effects and does not prevent recurrence. Intravitreal drug administration can improve disease outcomes and reduce side effects. Herein, we conducted a systematic review and meta-analysis on the efficacy of intravitreal injections for treating ocular toxoplasmosis.

29 July 2020 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
BSBárbara R. Silvestrini
Bárbara R. Silvestrini
JVJuliana Vieira
Juliana Vieira
MPMayara Rodrigues Brandao de Paiva
Mayara Rodrigues Brandao de Paiva
LSLuciana M. Silva
Luciana M. Silva
RJRodrigo Jorge
Rodrigo Jorge
The authors developed a retinoblastoma model using fresh harvested cells from an enucleated eye that were transplanted in chick embryos (chorioallantoic membrane model). The transplanted embryos were treated with escalating doses of Melphalan. This exploratory model was developed with the goal of testing drug sensitivity. Our findings suggest this tumor model could be employed to personalize treatment for patients with retinoblastoma, especially those with bilateral and more refractory disease.